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Strategies for iron supplementation: Oral versus intravenous. that an inadequate iron supply to the bone marrow is the
Iron supplementation has become an integral part of the man- most common cause of an impaired response to epoetin,
agement of patients receiving epoetin therapy, and clinicians and that iron supplementation is frequently required,have found it necessary to learn how and when to use it to the
possibly in up to 90% of patients treated [1]. Nephrolo-best advantage. Three routes of administration for iron are
gists have found it necessary to understand the complexi-available: oral, intramuscular, and intravenous. Oral iron has
the advantage of being simple and cheap, but it is limited ties of iron metabolism, to differentiate between absolute
by side-effects, poor compliance, poor absorption, and low and functional iron deficiency, to recognize the value of
efficacy. Intravenous iron is the best means of guaranteeing the various tests of iron status, and to develop strategiesdelivery of readily available iron to the bone marrow, but it
for giving patients supplemental iron therapy [2]. Therequires greater clinical supervision. The i.v. iron preparations
latter can be given in several different clinical situations:vary widely in their degradation kinetics, bioavailability, side-
effect profiles, and maximum dose for single administration. (a) as an alternative to epoetin therapy with the aim of
Iron dextran is hampered by a small but significant risk of achieving a modest rise in hemoglobin, particularly when
anaphylaxis, whereas all i.v. iron preparations can induce “free economic constraints limit the use of epoetin; (b) prioriron” reactions if the circulating plasma transferrin is over-
to epoetin therapy to boost the iron stores prophylac-loaded. Intravenous iron may be given in advance of epoetin
tically; (c) as a treatment for absolute or functional irontherapy, as concomitant treatment to prevent the development
of iron deficiency, as treatment of absolute or functional iron deficiency developing in patients receiving epoetin; and
deficiency, or as adjuvant therapy to enhance the response to (d) as an adjuvant therapy to enhance the response to
epoetin in iron-replete patients. Markers of iron status that epoetin even in iron-replete patients.may indicate a need for i.v. iron include a serum ferritin of
The aim of this article is to discuss the various regimensless than 100 mg/liter, a transferrin saturation of less than 20%,
available for supplementing iron in patients with renaland a percentage of hypochromic red cells more than 10%.
Various regimens are available for giving i.v. iron: low-dose anemia. Three routes of administration are available:
administration of 20 to 60 mg every dialysis session in hemodial- oral, intramuscular, and intravenous. The first two have
ysis patients, medium-dose administration of 100 to 400 mg,
severe limitations, particularly in the context of patientsand high-dose administration of 500 to 1000 mg. Iron sodium
receiving epoetin therapy, and the intravenous route isgluconate can only be given as a low-dose regimen because of
toxicity, whereas the only preparation suitable for high-dose increasingly used in such patients.
administration is iron dextran. Although concerns have been
raised regarding iron overload and long-term toxicity with i.v.
iron therapy in terms of increased risk of infections, cardiovas- ORAL IRON
cular disease, and malignancy, there is little evidence to sub-
Several iron salts are available in tablet or liquid formstantiate this in patients receiving epoetin. Care should be taken,
for oral ingestion, as listed in Table 1. All of these arehowever, to prevent the serum ferritin rising above 800 to 1000
mg/liter and the transferrin saturation above 50%. Provided fairly simple and cheap, but usually two or three doses
this is done, the benefits of i.v. iron almost certainly outweigh are required daily. Despite claims by some manufactur-
the risks in terms of optimizing the response to epoetin therapy. ers to the contrary, there is little advantage in the use
of any one oral preparation over any other. Ferrous
sulfate, which supplies 65 mg of elemental iron per 200
When epoetin therapy was first introduced into clinical mg tablet, is the most widely used oral iron preparation.
practice 10 years ago, the development of functional iron The main drawbacks with oral iron are side-effects,
deficiency and the need for iron supplementation were poor compliance, and limited absorption from the gut.
scarcely anticipated. It has since become very apparent Gastrointestinal intolerance with oral iron therapy is
dose related and common (up to 20% of patients), and
this frequently leads to poor compliance [3]. ToleranceKey words: epoetin therapy, transferrin, anaphylaxis, hypochromic red
cells, bone marrow, renal anemia. can be improved by ingesting the iron tablets along with
food, but this is associated with a corresponding decrease 1999 by the International Society of Nephrology
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Table 1. Available oral and parenteral iron preparationsa time of writing this article, the only licensed iron com-
pound in the United States is iron dextran (two differentIntravenous Intramuscular
Oral preparations preparations preparations formulations). In the United Kingdom, the only iron
Ferrous sulfate Iron dextranc Iron sorbitol citrate preparation with a product license is iron hydroxysac-
Ferrous fumarate Iron dextrinc charate (Venofer). In France, iron dextrin (polymaltose),
Ferrous gluconate Iron hydroxysaccharate
iron hydroxysaccharate, and iron sodium gluconate areFerrous succinate Iron sodium gluconate
Iron polymaltoseb all available. In Germany, both iron hydroxysaccharate
Polysaccharide- and iron sodium gluconate are used, and in Australia,
iron complex
both iron dextrin and iron hydroxysaccharate are avail-
a This list is not exhaustive; other oral and parenteral iron preparations may able.be available
b Can also be administered parenterally (intravenous or intramuscular injection) These different iron preparations vary greatly in their
c Can also be administered by intramuscular injection molecular size, their degradation kinetics (how rapidly
iron is released from the complex), their bioavailability,
and their side-effect profiles. In general, the smaller the
complex, the more rapidly iron is released to bind toin iron absorption. Furthermore, if functional iron defi-
transferrin and to supply the marrow [9].ciency develops in patients receiving epoetin who have
The concern with lower molecular weight complexesa serum ferritin above 100 mg/liter, then gastrointestinal
such as iron sodium gluconate is that iron may be re-absorption of iron will also be severely impaired [4].
leased too rapidly and may overload the ability of trans-All of these factors limit the usefulness of oral iron
ferrin to bind it, leading to free iron reactions [10]. Thus,supplementation in patients on epoetin, and administra-
lower doses of this iron preparation must be used (62.5tion of adequate amounts of iron orally is often impossi-
to 125 mg) compared with, for example, iron dextran,ble. This is because the demands for iron during epoetin
1000 mg of which may be given safely. A randomizedtreatment frequently exceed the maximum quantity that
prospective study compared 200 mg of i.v. iron dextran,can be supplied via the oral route. Indeed, comparative
iron dextrin, and iron hydroxysaccharate and found thatstudies of oral and i.v. iron have shown that only the
iron was released onto transferrin more rapidly with ironlatter is capable of providing an adequate supply of iron
hydroxysaccharate compared with the other two prepa-during epoetin treatment [5–8]. In such situations, the
rations, and that the increases in serum ferritin wereuse of parenteral iron preparations becomes a necessity
least marked with iron dextran [9]. A comparison ofin order to optimize the therapeutic response to epoetin.
different dosages of iron hydroxysaccharate given intra-
venously over two hours suggested that doses of 200 mg
INTRAMUSCULAR IRON or 300 mg could be administered safely, but that “free
iron” reactions were observed when doses of 400 mgThis route is little used in patients receiving epoetin,
although there are a few centers that supplement iron (incidence 6%) and 500 mg (incidence 36%) were given
[11].intramuscularly. Several preparations are available for
intramuscular administration (Table 1) and, as for oral The other major adverse effect, which is exclusively
seen with iron dextran, is anaphylaxis, which may beiron, there is little evidence to suggest that any one com-
pound is better than any other. There are several disad- life-threatening (see below). For this reason, a test dose
is strongly advised before administering a full treatmentvantages of the intramuscular route. First, the injections
are painful and can leave a brownish discoloration on dose of this preparation.
the skin that can persist for several weeks. Second, there
is a risk of bleeding into the muscle, which is exacerbated WHEN TO USE INTRAVENOUS IRON
by uremic platelet dysfunction in renal patients. Third,
Nephrologists vary widely in their usage of i.v. iron inthere are reports of muscle sarcomas developing at the
dialysis patients, with some adopting fairly aggressivesite of injection, and finally, the absorption and bioavail-
protocols aiming to keep the serum ferritin above 200ability from this route can be highly variable. Few studies
mg/liter and others using it only when all else fails. Al-have examined in any detail the use of intramuscular
though all markers of iron status have their limitations,iron in patients receiving epoetin therapy.
it is reasonable to consider using i.v. iron if the serum
ferritin is less than 100 mg/liter, the transferrin saturation
INTRAVENOUS IRON is less than 20%, or the percentage of hypochromic red
cells is more than 10%. Administering i.v. iron to iron-The use of i.v. iron has increased dramatically over the
last five years. Several i.v. iron preparations are available deficient patients will often induce a mild to moderate
increase in hemoglobin concentration by 1 to 2 g/dl evenworldwide (Table 1), although each country may have
access to only one or two of them. For example, at the in the absence of epoetin, and indeed, this practice was
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Table 2. Studies of aggressive i.v. iron supplementation in
patients receiving EPO
EPO
No. of Iron dose
Reference patients preparation reduction
Schaefer & Schaefer (1992) [16] 14 gluconate 47%
Nyvad et al (1994) [17] 34 sucrose 27%
Al-Momen et al (1994) [18] 109 sucrose —
Sunder-Plassmann & Ho¨rl
(1995) [19] 64 sucrose 70%
Fishbane et al (1995) [20] 52 dextran 46%
Macdougall et al (1996) [22] 37 dextran 19%
Silverberg et al (1996) [23] 41 sucrose 61%
Sepandj et al (1996) [24] 50 dextran 35%
Taylor et al (1996) [25] 46 gluconate 33%
Ahsan et al (1996) [26] 7 dextran 26%
adopted by some clinicians long before the advent of
epoetin [12, 13]. Even today, there are those who believe
that the maximum gain should be obtained from i.v. iron
before the more costly epoetin therapy is instituted [14].
The second clinical situation in which i.v. iron is used
is in preparation for epoetin therapy where the iron
stores, as judged by the serum ferritin, are likely to be
inadequate to support a rise in hemoglobin concentra-
Fig. 1. Hemoglobin response (mean 6 SD) in three groups of erythro-
tion of 4 to 5 g/dl. Previous work suggested that a serum poietin-treated patients with different regimens of iron supplementa-
tion. Symbols are: (d) i.v. iron; (s) oral iron; (j) no iron; *P , 0.05;ferritin of 20 mg/liter was required for every 1 g/dl of
**P , 0.005 vs. i.v. iron-treated group. Taken from Macdougall et alhemoglobin [15]. Thus, patients due to start epoetin ther-
[22]; used with permission.
apy with a ferritin of less than 100 mg/liter are highly
likely to develop iron deficiency, and in such patients, it
is advisable to start i.v. iron concomitantly.
The third scenario when i.v. iron is given is when a this wide variability is that some of the studies included
patients with absolute iron deficiency when one wouldpatient on epoetin develops either absolute or functional
iron deficiency. Absolute iron deficiency is easier to diag- expect i.v. iron to be even more effective. Several studies,
however, examined only iron-replete patients, and twonose and is present when the serum ferritin falls below
50 mg/liter in dialysis patients. Functional iron deficiency in particular were conducted as randomized prospective
controlled trials, with an oral iron control arm. Macdou-is harder to recognize; the serum ferritin is normal or
high, and the problem is with adequate amounts of avail- gall et al randomized 37 iron-replete (ferritin of more
than 100 mg/liter) patients to receive either i.v. iron dex-able iron being delivered to the marrow. This is usually
manifest by a transferrin saturation value of less than tran (N 5 13), oral iron (ferrous sulfate 200 mg tds; N 5
12), or no iron supplementation (N 5 12) during the20% or a hypochromic red cell measurement of more
than 10%. Oral iron is useless in this condition because correction phase of epoetin therapy [22]. The group of
patients treated with regular i.v. iron had the best hemo-very low levels are absorbed [4], and i.v. iron is manda-
tory to optimize the response to epoetin and to prevent globin response, maintained their serum ferritin at pre-
treatment levels, and had the lowest dose requirementswastage of this costly drug.
The final clinical context that has received a lot of of epoetin (Fig. 1). Similarly, in a study by Fishbane et
al, 52 dialysis patients in the correction phase of epoetinattention in recent years is the aggressive use of i.v. iron
supplementation to enhance the response to epoetin, therapy who had ferritin levels of more than 100 mg/liter
were randomized to receive either i.v. iron dextran (N 5even in patients who are iron replete [16–27]. The ratio-
nale for this is that iron supply to the erythron is a rate- 32) or oral iron (N 5 20) [20]. Again, the hematocrit
level increased significantly in the i.v. iron group com-limiting step in the process of erythropoiesis and that
this can be overcome by administering iron in a readily pared with the oral iron group, and substantial reductions
in epoetin dose requirements were seen (Fig. 2). Thereavailable form intravenously. Some of the studies that
have supported the development of this practice are seems little doubt, therefore, that in order to maximize
the response to epoetin therapy, i.v. iron will be requiredlisted in Table 2, and reductions in epoetin dosage have
varied widely from 19% to 70%. Part of the reason for in a substantial number of patients.
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Table 3. Regimens for administering i.v. iron
“Low dose” 20–60 mg every dialysis session
• hemodialysis patients only
• any of iron preparations suitable
• may be given as i.v. “push”
“Medium dose” 100–400 mg
• usually i.v. infusion; lower doses may be given
as slow bolus injection
• all iron preparations (maximum dose of iron
sodium gluconate 5 62.5–125mg)
“High dose” 500–1000 mg
• must be given as i.v. infusion
• only iron dextran suitable
• suitable as a top-up for patients with large iron
deficit
these agents may be given as an i.v. “push” [28]. Medium-
dose administration of 100 to 400 mg may be provided
by either iron hydroxysaccharate, iron dextrin, or iron
Fig. 2. Mean hematocrit in two groups of patients receiving erythropoi- dextran, and is practical for once-weekly or once-fort-
etin. Squares indicate the intravenous iron group; diamonds indicate
nightly administration. Again, a single dose of 100 mgthe oral iron group. *P , 0.05. Taken from Fishbane et al [20]; used
with permission. can be given as a slow i.v. injection, whereas doses of
200 mg or more should be given as an i.v. infusion. High-
dose i.v. iron supplementation is less popular than before
because side-effects such as arthralgia, myalgia, and
POSSIBLE REGIMENS FOR ADMINISTERING other aches and pains are more common at this dose.
INTRAVENOUS IRON The only i.v. iron preparation that can be given as a
single dose of 500 to 1000 mg is iron dextran, which mustApart from the kinetic bioavailability study mentioned
be administered as a slow infusion over several hours.earlier [9], there are no randomized controlled prospec-
This dose would, however, be practical for a patient whotive studies comparing one i.v. iron preparation with
lives a considerable distance from hospital or who isanother. It seems likely, however, that there will be little
unwilling to attend more than once every three to fourto distinguish them in terms of efficacy, and that what
months.matters most is the recognition that many patients on
epoetin will require i.v. iron supplementation in one form
or another. MONITORING INTRAVENOUS
The two most important factors determining which IRON SUPPLEMENTATION
i.v. iron regimen will be used are (a) modality of renal
Patients receiving regular i.v. iron should be moni-replacement therapy and (b) what iron preparations are
tored closely for clinical or laboratory evidence of ironavailable in the particular country of origin. For example,
toxicity or overload. Abnormal liver function tests, awith hemodialysis patients, it is practical to give doses
serum ferritin greater than 800 to 1000 mg/liter, or aof 20 to 60 mg three times a week during each dialysis
transferrin saturation greater than 50% may all indicate
session. This is not the case with continuous ambulatory
iron overload and increase the risk of parenchymal depo-
peritoneal dialysis (CAPD) or predialysis patients, who sition of iron in the liver, pancreas, and heart. The aim
would far prefer to receive a larger dose of 200 to 500 should be, therefore, to monitor these parameters regu-
mg once a month. At the time of writing this article, iron larly and stop i.v. iron if these levels are exceeded. Serum
dextran is the only preparation available in the United ferritin and transferrin saturation should be measured
States (although this is changing), and thus, this clearly at least one week after administration of i.v. iron for
limits the choice of i.v. iron regimen in this country. modest doses (100 to 200 mg) [9] and at least two weeks
It is perhaps convenient to consider the various strate- after i.v. iron for larger doses, in order to exclude a
gies available as “low-dose,” “medium-dose,” and “high- spuriously high measurement.
dose” i.v. iron (Table 3). Iron sodium gluconate is useful
for only low-dose administration because its toxicity lim-
REACTIONS TO INTRAVENOUS IRONits the dose to a maximum single administration of 62.5
to 125 mg. Iron hydroxysaccharate, iron dextrin, or iron There appear to be two types of reaction to i.v. iron.
The first is a type I IgE-mediated anaphylactic reaction,dextran may also be used for this purpose, and all of
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which is seen exclusively to iron dextran and is due to optimize the benefits of epoetin therapy and can result
in dosage (and hence cost) reductions.preformed dextran antibodies. The reported incidence of
anaphylaxis to iron dextran is approximately 0.7% [29].
Reprint requests to Dr. Iain C. Macdougall, Consultant Nephrologist,The second reaction is anaphylactoid in nature, caus-
Renal Unit, King’s College Hospital, East Dulwich Grove, London
ing one or more symptoms such as breathlessness, wheez- SE22 8PT, England, United Kingdom.
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